Abstracts Archive - Page 283 of 2425 - ACR Meeting Abstracts

Abstract Number: 0979 • ACR Convergence 2023
Use and Discontinuation of Tumour Necrosis Factor Inhibitors Among Pregnant Women with Chronic Inflammatory Diseases
Leah K. Flatman¹, Sasha Bernatsky², Isabelle Malhamé³, Yvan St. Pierre², Olga Basso¹, Anick Bérard⁴ and Evelyne Vinet⁵, ¹McGill University, Montreal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³McGill University Health Centre, Montreal, QC, Canada, ⁴University of Montreal, Montreal, QC, Canada, ⁵McGill University Health Centre, Montréal, QC, Canada
Background/Purpose: Early consensus statements recommended discontinuing tumour necrosis factor inhibitors (TNFi) during pregnancy. Despite new guidelines recommending against this, the choice to stop TNFi pre-conception…
Abstract Number: 1775 • ACR Convergence 2023
The Peptidyl Arginine Deiminase Inhibitor BB-CLA Decreases the Inflammatory and Fibrotic Responses in Macrophages and Rheumatoid Arthritis Synovial Fibroblasts Exposed to Fibrinogen Modified with Malondialdehyde-Acetaldehyde Adduct and Citrulline
Jack Mordeson¹, Nozima Aripova¹, Michael Duryee¹, James O'Dell¹, Bryant England¹, Daniel Anderson¹, Ted R Mikuls² and Geoffrey Thiele¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Peptide citrullination and adduction with malondialdehyde-acetaldehyde adduct (MAA) are post-translational modifications involved in the pathogenesis of rheumatoid arthritis (RA). Anti-cyclic-citrullinated peptide antibodies are >90%…
Abstract Number: 1670 • ACR Convergence 2023
Exacerbation of Immune-mediated Inflammatory Diseases in COVID19 Sequelae
CAMILA CAETANO¹, Tamiris Azamor¹, Nikki M. Meyer¹, Cassandra Calabrese², Leonard Calabrese², Nicolas Piuzzi³, M. Elaine Husni², Suan-Sin Foo¹ and Weiqiang Chen¹, ¹Cleveland Clinic / Infection Biology Program, Global Center for Pathogen Research and Human Health, Lerner Research Institute, Cleveland, OH, ²Cleveland Clinic / Department of Rheumatic and Immunologic Diseases, Cleveland, OH, ³Cleveland Clinic / Department of Orthopedic Surgery, Cleveland, OH
Background/Purpose: Patients with underlying immune-mediated inflammatory diseases (IMIDs), such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), have a higher susceptibility to severe COVID19…
Abstract Number: 1739 • ACR Convergence 2023
Mass Spectrometry Identified Rheumatoid Arthritis-Specific Modified Proteins and the Discovery of Antigen-Specific Hidden Autoantibodies
Khetam Ghannam¹, Marieluise Kirchner², Holger Bang³, Thomas Häupl⁴, Sarah Ohrndorf¹, Jan Zernicke¹, Ulrike Kuckelkorn⁵, Philipp Mertins⁶, Eugen Feist⁷ and Gerd Burmester⁸, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, ²Proteomics Platform at Max Delbrück Center for Molecular Medicine and Berlin Institute of Health (BIH), Berlin, Germany, ³Orgentec Diagnostika GmbH, Mainz, Germany, ⁴Helios Department of Rheumatology, Vogelsang-Gommern, Germany, ⁵Institute of Biochemistry, Berlin, Germany, ⁶Proteomics Platform at Max Delbrück Center for Molecular Medicine and Berlin Institute of Health (BIH), Berlin, Germany, ⁷Helios Department of Rheumatology and Clinical Immunology, Vogelsang-Gommern, Germany, ⁸Charité – Universitätsmedizin Berlin, Department of Rheumatology and Clinical Immunology, Berlin, Germany
Background/Purpose: Rheumatoid arthritis (RA) is a chronic and systemic autoimmune disease characterized by synovial inflammation and progressive joint destruction. Given the presumed pathophysiologic role of…
Abstract Number: 1656 • ACR Convergence 2023
Nothing About Us Without Us: Top 10 Research Priorities from Patients – A James Lind Alliance Project for Public and Patient Involvement (PPI)
anna Fryxelius¹, Amy Martinsen², Ida Løchting³, Linda Aimee Hartford Kvæl⁴, Astrid Lunestad², Astrid Bergland⁴ and Kjersti Storheim², ¹Norwegian Rheumatism Association / REMEDY - Center for Treatment of Rheumatic and Musculoskeletal Diseases, Oslo, Norway, ²Oslo University Hospital, Oslo, Norway, ³REMEDY - Center for Treatment of Rheumatic and Musculoskeletal Diseases, Oslo, Norway, ⁴OsloMET, Oslo, Norway
Background/Purpose: Patient and public involvement (PPI) is gaining increasing recognition as important to ensure research is relevant and to reduce avoidable research waste. Active collaboration…
Abstract Number: 1547 • ACR Convergence 2023
Disease Burden of Eosinophilic Granulomatosis with Polyangiitis (EGPA): A Retrospective Analysis of US Health Insurance Claims Data
Paul Dolin¹, Danuta Kielar¹, Anat Shavit¹, Karina Keogh², Jennifer Rowell¹, Chris Edmonds³, Juliana Meyers⁴, Elizabeth Esterberg⁴, Tram Nham⁴ and Stephanie Chen⁵, ¹AstraZeneca, Cambridge, United Kingdom, ²Mayo Clinic, Rochester, MN, ³AstraZeneca, Gaithersburg, MD, ⁴RTI Health Solutions, Research Triangle Park, NC, ⁵BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare necrotizing small-to-medium vessel vasculitis with a relapsing-remitting course involving prodromal (various allergic reactions), eosinophilic (infiltration into…
Abstract Number: 0973 • ACR Convergence 2023
Real-World Comparative Effectiveness Study of Janus Kinase Inhibitors Compared to Biologic Disease Modifying Antirheumatic Drugs in Korean Patients with Rheumatoid Arthritis
Soo-Kyung Cho¹, Yeo-Jin Song¹, Jungyong Han², Hye Won Kim³, Eunwoo Nam³, Sang Won Lee⁴, Shin-Seok Lee⁵, Hye-Soon Lee⁶, Sung-Hoon Park⁷, Yeon-Ah Lee⁸, Sung Hae Chang⁹, Min-Chan Park¹⁰, Hyoun-Ah Kim¹¹, Hyun-Sook Kim¹², Bo Young Yoon¹³, Yong-Gil Kim¹⁴, Hae-Rim Kim¹⁵, Jae Hoon Kim¹⁶, Jisoo Lee¹⁷, Jeongim Choi¹⁸, Wan-Sik Uhm¹⁹ and Yoon-Kyoung Sung¹, ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ³Hanyang University Institute for Rheumatology Research, Seoul, South Korea, ⁴Hanyang University, Seoul, South Korea, ⁵Chonnam National University Medical School & Hospital, Gwangju, South Korea, ⁶Hanyang University, Guri, South Korea, ⁷Daegu Catholic University School of Medicine, Daegu, South Korea, ⁸Kyung Hee University Hospital, Seoul, South Korea, ⁹Soonchunhyang University College of Medicine, Bongmyeong-dong, Dongnam-gu, Cheonan-si, South Korea, ¹⁰Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea, ¹¹Ajou University School of Medicine, Suwon, South Korea, ¹²Soonchunhyang University Seoul Hospital, Seoul, South Korea, ¹³Inje University Ilsan Paik Hospital, Goyang, South Korea, ¹⁴Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea, ¹⁵Rheumatology, Konkuk University Medical Center, Seoul, South Korea, ¹⁶Korea University Medical Center, Seoul, South Korea, ¹⁷Ewha Womans Univ College of Medicine, Seoul, South Korea, ¹⁸Busan Saint Mary's Hospital, Busan, South Korea, ¹⁹Uhm's Rheumatism Clinic, Seoul, South Korea
Background/Purpose: Although clinical trials have shown similar effectiveness between Janus kinase inhibitors (JAKi) and biologic disease-modifying anti-rheumatic drugs (bDMARDs), the choice between these two options…
Abstract Number: 0990 • ACR Convergence 2023
Association of Treatment and Disease Activity with Antibiotic Use and Hospitalized Infection Among People Living with Rheumatoid Arthritis: Baseline Data from a Longitudinal Study in the ArthritisPower Registry
Kelly Gavigan¹, Esteban Rivera², Odette Kolenky³, Cassie Clinton⁴, Emily Holladay⁴, David Curtis⁵, Laura Stradford⁶, Jeffrey Curtis⁴, W. Benjamin Nowell⁶, Christian Curtis⁷ and Michael George⁸, ¹Global Healthy Living Foundation, Upper Nyack, NY, ²Global Healthy Living Foundation, Long Island City, NY, ³Hospital of the University of Pennsylvania, Philadelphia, PA, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Global Healthy Living Foundation, San Francisco, CA, ⁶Global Healthy Living Foundation, Nyack, NY, ⁷Illumination Health, Birmingham, AL, ⁸University of Pennsylvania, Philadelphia, PA
Background/Purpose: Infections are a major contributor to morbidity and mortality in patients (pts) with rheumatoid arthritis (RA). Little is known about the risk of non-serious…
Abstract Number: 1288 • ACR Convergence 2023
Frailty Is Associated with Higher Risk of Readmission in Patients with Rheumatoid Arthritis
Waqas Tahir¹, Yenny Rosli², Christopher Leung³, K Wysham⁴, Jiha Lee⁵, Radjiv Goulabchand⁶, Una Makris⁷, Siddharth Singh⁸ and Namrata Singh⁹, ¹Mayo Clinic, Jacksonville, FL, ²University of Washington, Seattle, WA, ³Georgetown University School of Medicine, Washington, DC, ⁴VA Puget Sound/University of Washington, Seattle, WA, ⁵University of Michigan, Ann Arbor, MI, ⁶University of California San Diego, La Jolla, CA, ⁷UT Southwestern Medical Center and Dallas VA, Dallas, TX, ⁸University of California San Diego, San Diego, CA, ⁹University of Washington, Bellevue, WA
Background/Purpose: With the advent of new therapies and increasing life expectancy, there is a rising number of older adults living with rheumatoid arthritis (RA). Patients…
Abstract Number: 1771 • ACR Convergence 2023
Role of Periostin in the Pathophysiology and Accurate Diagnosis of Interstitial Lung Disease Associated with Autoimmune Diseases
Verónica Pulito-Cueto¹, David Iturbe-Fernández², Victor Mora-Cuesta², Joao Carlos Batista-Liz¹, Belén Atienza-Mateo³, María Sebastián-Mora¹, Virginia Portilla¹, Alfonso Corrales¹, Miguel A Gonzalez-Gay⁴, Jose Cifrian⁵, Ricardo Blanco¹ and Raquel López-Mejías¹, ¹Rheumatology Department, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, ²Immunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL; Department of Pneumology, Marqués de Valdecilla University Hospital, Santander, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain, ⁵Immunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL; Department of Pneumology, Marqués de Valdecilla University Hospital; School of Medicine, Cantabria University, Santander, Spain
Background/Purpose: Periostin is an extracellular matrix protein that contributes to the development and repair of lung tissue [1]. Previous works have described periostin as a…
Abstract Number: 1667 • ACR Convergence 2023
Characterization of the Vascular Niches in Systemic Sclerosis (SSc) as a Prototypical Immune-mediated Fibrotic Disease with Prominent Vasculopathy Using Imaging Mass Cytometry
Minrui Liang¹, Aleix Rius Rigau², yi-nan Li¹ and Joerg Distler¹, ¹Clinic for Rheumatology University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany, ²Department of Internal Medicine 3, Rheumatology and Clinical Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany; Deutsches Zentrum Immuntherapie (DZI), FAU Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany
Background/Purpose: Systemic sclerosis (SSc) is a prototypical collagen-vascular disease with prominent vasculopathy. Although microvascular changes are the earliest histopathologic manifestation of SSc, the vascular dysregulation…
Abstract Number: 1773 • ACR Convergence 2023
Integrated Analysis of Rheumatoid Arthritis (RA) Fibroblast-like Synoviocytes (FLS) Transcriptome and Chromatin Accessibility Identifies Mechanisms Associated with Location-specific Disease Severity
Eunice Choi¹, Camilla R. L. Machado², David Boyle¹, Wei Wang¹ and Gary Firestein², ¹University of California San Diego, La Jolla, CA, ²University of California San Diego, San Diego, CA
Background/Purpose: Mechanisms responsible for the distribution and severity of joint involvement in RA are not known. To explore whether site-specific FLS biology might contribute to…
Abstract Number: 1741 • ACR Convergence 2023
The Occurrence and Phenotype of Autoreactive T Cells in the At-Risk Phase of Rheumatoid Arthritis
Sara Turcinov¹, Charlotte de Vries², Ravi Kumar Sharma², Christina Gerstner², Bruno Raposo², Anatoly Dubnovitsky², William Kwok³, Karine Chemin², Vivianne Malmström⁴ and Aase Hensvold⁵, ¹Division of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska Institutet. Theme of Inflammation and Ageing, Medical Unit Gastro, Derma, Rheuma, Karolinska University Hospital, Stockholm, Sweden, ²Division of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ³Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁴Karolinska Institutet, Stockholm, Sweden, ⁵Division of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska University Hospital, Karolinska Institutet. Center for Rheumatology, Academic Specialist Center, Stockholm, Sweden
Background/Purpose: CD4+ T cells recognizing citrullinated epitopes are present in peripheral blood of anti-citrulline protein antibody (ACPA) positive rheumatoid arthritis (RA) patients at time of…
Abstract Number: 1676 • ACR Convergence 2023
Tofacitinib Accelerates in Vitro Clot Formation and Delays Clot Lysis in Rheumatoid Arthritis Blood by Enhancement of Macrophage TLR4 Mediated Cytokine Responses- a New Angle on Thrombosis with JAKi in Rheumatology
Paula David¹, Thomas Macleod², Yu Shi³, Payal Ganguly¹, Cedric Duval³, Mark Harland¹, Chi Wong¹, Benazir Saleem⁴ and Dennis McGonagle⁵, ¹University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), Leeds, United Kingdom, ²University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ³Discovery and Translational Science Department, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United Kingdom, ⁴Leeds Teaching Hospitals NHS Trust, Rheumatology, Chapel Allerton Hospital, Leeds, United Kingdom, ⁵Leeds Biomedical Research Centre, University of Leeds, Leeds, United Kingdom
Background/Purpose: Rheumatoid Arthritis (RA) patients treated with Janus Kinase inhibitors (JAKi) have reportedly higher venous thromboembolism (VTE) risk and atherosclerotic-related complications including myocardial infarction (1).Although…
Abstract Number: 1549 • ACR Convergence 2023
Treatment Patterns for Eosinophilic Granulomatosis with Polyangiitis (EGPA): A Retrospective Analysis of US Health Insurance Claims Data
Paul Dolin¹, Danuta Kielar¹, Anat Shavit¹, Karina Keogh², Jennifer Rowell¹, Chris Edmonds³, Juliana Meyers⁴, Elizabeth Esterberg⁴, Tram Nham⁴ and Stephanie Chen⁵, ¹AstraZeneca, Cambridge, United Kingdom, ²Mayo Clinic, Rochester, MN, ³AstraZeneca, Gaithersburg, MD, ⁴RTI Health Solutions, Research Triangle Park, NC, ⁵BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare, immune-inflammatory disorder characterized by asthma, eosinophilia, eosinophil-rich granulomatous inflammation, and chronic necrotizing vasculitis of small-to-medium-sized blood…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].